Tioxacin

Tioxacin

SCHEMBL2109483

CCn1cc(C(=O)O)c(=O)c2c3sc(=O)n(C)c3ccc21

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.50
HPGD P15428 5/20 0.50
ALDH1A1 P00352 5/20 0.50
HSD17B10 Q99714 4/20 0.50
TSHR P16473 3/20 0.50
RAB9A P51151 1/20 0.50
CYP1A2 P05177 2/20 0.44
CYP2D6 P10635 1/20 0.44
APEX1 P27695 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 6/20 0.44
HTT P42858 3/20 0.44
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ABCC4 O15439 1/20 0.41
PKM P14618 1/20 0.41
PTGS1 P23219 1/20 0.41
DRD3 P35462 1/20 0.39
FOXO1 Q12778 1/20 0.39
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11687691 0.80 ALDH1A1 (0.37) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL11576271 0.77 KDM4E (0.52) KDM4EHPGDALDH1A1HSD17B10TSHR
Metioxate SCHEMBL2110273 0.76 HPGD (0.46) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL14845181 0.75 KDM4E (0.55) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL8627262 0.74 ALDH1A1 (0.54) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL15999546 0.74 KDM4E (0.54) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL8625170 0.72 KDM4E (0.52) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL23924269 0.69 HPGD (0.49) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL11278972 0.69 KDM4E (0.48) KDM4EHPGDALDH1A1HSD17B10TSHR
SCHEMBL11278950 0.69 KDM4E (0.48) KDM4EHPGDALDH1A1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
CN-102822163-B Crth2 modulators IRONWOOD PHARMACEUTICALS, INC. (US) 2016-01-20 CN disclosed
CN-104684920-A Antimicrobial and foamable alcoholic compositions GOJO IND INC 2015-06-03 CN disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
US-4054568-A ANTIBACTERIAL SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-10-18 US disclosed
US-3954775-A FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-05-04 US disclosed
US-3953428-A ANTIBACTERIAL YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) 1976-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 KDM4E 4426/4885HPGD 4399/4885ALDH1A1 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.